{
  "docId": "019dd923-622c-750b-8b9a-21918ac10c17",
  "docSlug": "f3db2294dcf9",
  "documentTitle": "Harmony Biosciences (HRMY)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-03-28 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 209,
  "pageCount": 366,
  "prevPage": 208,
  "nextPage": 210,
  "slideType": "precedent_table",
  "function": "expose_contradiction",
  "density": "balanced",
  "nDataPoints": 15,
  "notes": "The slide uses a table to contrast the clinical trial design with the author's thesis that the evidence standard is too low.",
  "elementsJson": [
    "paragraph",
    "data_table"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-21918ac10c17/209",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17#slide-209",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "The foreign clinical trials that led to the approval of pitolisant are a poster child for the weaknesses and loopholes in the FDA's fast-track approval process, where a far lower standard of evidence is acceptable for a rare indication.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64d1-73a9-abb4-c0573837a2c7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "paragraph",
      "text": "The foreign clinical trials that led to the approval of pitolisant are a poster child for the weaknesses and loopholes in the FDA's fast-track approval process, where a far lower standard of evidence is acceptable for a rare indication.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd934caf-9534-4fc5-9d2c-9205d0ddd9d4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "Harmony investor presentation, Nov 2022",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64d1-73a9-abb4-c73525b499c5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.5,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: https://ir.harmonybiosciences.com/static-files/f5315c60-3f1e-4207-aa4f-53bff52dbe54",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b4f2d54b-fb31-4518-94c1-d1d435d5b022",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.38,
        "w": 0.86,
        "x": 0.07,
        "y": 0.54
      },
      "kind": "table",
      "text": "Table showing HARMONY 1, 1bis, CTP, 3, and Human Abuse Potential Study with columns for Study Design, N, Dose, Objective, and Results.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3c7ac4a1-ed1a-43f0-8dbe-c7b9ab7e02cb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.07,
        "y": 0.47
      },
      "kind": "title",
      "text": "WAKIX® Phase 3 Clinical Development Program",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a5daf700-62a4-484f-8f91-07c08a72e2a7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "f7d95e9a-bf7b-4bb2-abc0-31cbe4d32742",
      "evidence": "The slide explicitly frames the clinical trial data as evidence of 'weaknesses and loopholes' in the FDA approval process.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}